Other News

The MNAT initiative – what’s new?

Back in 2013, the European Medicines Agency (EMA) established a pilot scheme called the Multinational Assessment Team (MNAT) Initiative. For the assessment of new marketing authorisation applications, the MNAT provides the option for the EMA scientific committees to rely on an assessment team formed from national competent authorities (NCAs) of different European Union (EU) Member States in return for payment by the EMA to the individual NCAs.

In practice, every new marketing authorisation for human medicinal products submitted under the centralised procedure is assessed by a rapporteur and a co-rapporteur from the EMA Committee for Medicinal Products for Human Use (CHMP), or the EMA Committee for Advanced Therapies (CAT). These scientific committees are composed of individual experts from different NCAs who must choose teams of assessors and experts to support them. Traditionally, the scientific committees choose teams of assessors and experts from their respective NCAs. The MNAT Initiative is intended to encourage the scientific committees to form multinational co-rapporteur teams with the best expertise available from a broader number of EU Member States.

The overarching objective of the MNAT Initiative is to allow a broader involvement of NCAs from different EU Member States in the work of the EMA scientific committees. The logic behind this is to spread the workload and to broaden the expertise across the EU.  With the MNAT Initiative, the EMA is seeking to optimise the use of national resources, whilst maintaining the high quality scientific work of the EMA scientific committees.

In December 2016 the EMA endorsed the EMA document “Multinational assessment team concept: the next phase – Broadening the concept to the post-authorisation phase”. This document stipulates that, from April 2017, assessment teams consisting of different EU Member States NCAs will also be able to evaluate applications for extensions of marketing authorisations of existing medicinal products.

The expansion of the MNAT Initiative has been initially limited to assessments of applications for extensions of indications and line extension applications, relating to products in relation to which an MNAT was involved in evaluating the original marketing authorisation application. In July 2017, the EMA released further guidance to rapporteurs and coordinators managing MNAT procedures.  

Importantly, the EMA has also seen that the MNAT initiative is one possible way of finding a solution to the issue of Brexit and its reliance on United Kingdom experts and, once the UK leaves, to compensate for the loss of UK expertise.

Here at ELC Group we have a team of experts available and on-hand to help plan and manage your future EMA submissions, taking into consideration the rapidly changing regulatory environment and potential pitfalls in regulatory submission strategy.

Also see our

press coverage

News Index

14 Aug 2017

The MNAT initiative – what’s new?

19 Jul 2017

ICH Q12: Light at the end of the tunnel…?

05 Jun 2017

Q3D: Are your established products in compliance?

02 Jun 2017

Key pharmacovigilance trends to watch

08 May 2017

EMA updates guidance on PSURs

10 Apr 2017

New EMA Consultation on the Quality of Inhaled Pharmaceutical Products

16 Mar 2017

European Parliament’s adoption of ‘Options for improving access to medicines’ procedure

16 Feb 2017

Article 58: a hidden potential

24 Jan 2017

Global lifesciences partner ELC Group teams with PSR Group for advanced drug development

19 Jan 2017

A positive step forward for Biosimilar registration

20 Dec 2016

Falsified Medicines Directive – Are you making the right preparations?

21 Nov 2016

New Public consultation launched by the European Commission (EC)

19 Oct 2016

Transatlantic collaboration to boost research and development of medicines for rare diseases

03 Jun 2016

ELC Group to showcase regulatory affairs solutions at CPhI events in Shanghai and Barcelona

16 Jun 2015

ELC Group in early-stage development of novel influenza vaccine

09 Jun 2015

ELC Group expands into pharmaceutical product development market

21 Apr 2015

ELC Group signs 1.5 million Euro regulatory affairs contract with Chinese pharma giant

24 Feb 2015

Fast-growing regulatory affairs service provider ELC Group expands corporate presence in Czech Republic

02 Feb 2015

ELC GROUP to present at “Regulatory & Legal Affairs in Russia 2015” Conference

15 Sep 2014

Pharma eReport delivers V5-compliant solution to help MAHs meet December 31st XEVMPD resubmission deadline

20 Aug 2014

ELC Group Appoints Dr. Siddharth Chachad as Head of Global Clinical Development and Medical Affairs

28 Jul 2014

ELC Group Appoints Head of Regulatory Affairs for Russia and CIS

14 Apr 2014

Global regulatory affairs specialist ELC Group appoints Localization Business Development Manager for new US Office

10 Oct 2013

Global regulatory affairs specialist ELC Group accelerates international expansion plans following 25% revenue growth in 2013

17 Sep 2013

Global regulatory affairs specialist ELC Group appoints former MHRA Expert Medical Assessor

23 Apr 2013

Global regulatory affairs specialist ELC Group receives accreditation to provide readability testing in Romania

27 Feb 2013

Global regulatory affairs specialist ELC Group to deliver pharmaceutical training event in Latvia

20 Feb 2013

Global pharmaceutical regulatory affairs specialist ELC Group launches Clinical Trials services

10 Jan 2013

Global pharmaceutical regulatory affairs specialist ELC Group hosts International Training Seminar in Mumbai, India

31 Dec 2012

2012 Events

07 Nov 2012

Global pharmaceutical regulatory affairs specialist ELC Group establishes new office in Singapore

22 Aug 2012

Global pharmaceutical regulatory affairs specialist ELC Group increases operational support in Ahmedabad

12 Jun 2012

XEVMPD software provider Pharma eReport launches Excel Data Import Service

06 Jun 2012

ELC Group partners with mdi Europa GmbH to offer end-to-end regulatory solution for medical device companies in Europe

28 Mar 2012

ELC Group joins DIA EuroMeeting in Copenhagen

21 Mar 2012

EVMPD software provider Pharma eReport announces full general availability of Centrality XEVMPD compliance solution

08 Mar 2012

ELC Group Hosts Successful International Regulatory Seminar

06 Mar 2012

Pharmaceutical regulatory affairs specialist ELC Group opens new office in Mumbai

23 Feb 2012

Regulatory challenges for 2012 and their impact on marketing authorisation

21 Feb 2012

ELC Group launches new software subsidiary Pharma eReport to provide complete EVMPD compliance solution

08 Feb 2012

Pharmaceutical regulatory affairs specialist ELC Group establishes global HQ in Cambridge, UK

07 Dec 2011

Past president of TOPRA and ELC GROUP Advisor speaks at International Regulatory Seminar in Ahmedabad 23 February 2012

27 Sep 2011

ELC GROUP Advisory Board’s Dr. Paolo Biffignandi to write opinion column for industry leading publication

12 Jul 2011

ELC Group aim to foster strategic and economic ties within India and China

25 May 2011

ELC Group announces doubled revenues

11 May 2011

ELC Group appoints former TOPRA President